Insilico Medicine and Hygtia Therapeutics Enter New Global Strategic Collaboration to Co-Develop Novel Brain Penetrant NLRP3 Inhibitor for CNS Diseases treatment (IMAGE)
Caption
- Insilico Medicine and Hygtia Therapeutics, an incubatee of Shenzhen Pengfu Fund of Fosun Health Capital and Fosun Pharma, have entered into an exclusive license and co-development collaboration to advance ISM8969 worldwide. Under the agreement, both parties hold 50% worldwide rights, and Insilico is eligible to receive up to USD 66 million in upfront and milestone payments.
- Insilico will lead the IND submission and Phase 1 clinical trial of ISM8969, after which Hygtia Therapeutics will take responsibility for further clinical development, regulatory filings, and commercialization.
- ISM8969, an orally available, brain penetrant NLRP3 inhibitor discovered using Insilico’s generative AI platform Chemistry42, has demonstrated strong efficacy, favorable safety, and robust blood-brain barrier (BBB) penetration in preclinical studies.
Credit
Insilico Medicine
Usage Restrictions
None
License
Original content